Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8B5I

C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one

This is a non-PDB format compatible entry.
Summary for 8B5I
Entry DOI10.2210/pdb8b5i/pdb
Related8B5G 8B5H
DescriptorBromodomain-containing protein 2, 1,2-ETHANEDIOL, 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL, ... (5 entities in total)
Functional Keywordsinhibitor complex bromodomain, transcription
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight14282.46
Authors
Chung, C. (deposition date: 2022-09-22, release date: 2022-11-30, Last modification date: 2024-05-01)
Primary citationHumphreys, P.G.,Anderson, N.A.,Bamborough, P.,Baxter, A.,Chung, C.W.,Cookson, R.,Craggs, P.D.,Dalton, T.,Fournier, J.C.L.,Gordon, L.J.,Gray, H.F.,Gray, M.W.,Gregory, R.,Hirst, D.J.,Jamieson, C.,Jones, K.L.,Kessedjian, H.,Lugo, D.,McGonagle, G.,Patel, V.K.,Patten, C.,Poole, D.L.,Prinjha, R.K.,Ramirez-Molina, C.,Rioja, I.,Seal, G.,Stafford, K.A.J.,Shah, R.R.,Tape, D.,Theodoulou, N.H.,Tomlinson, L.,Ukuser, S.,Wall, I.D.,Wellaway, N.,White, G.
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
J.Med.Chem., 65:15174-15207, 2022
Cited by
PubMed Abstract: The bromodomain and extra terminal (BET) family of proteins are an integral part of human epigenome regulation, the dysregulation of which is implicated in multiple oncology and inflammatory diseases. Disrupting the BET family bromodomain acetyl-lysine (KAc) histone protein-protein interaction with small-molecule KAc mimetics has proven to be a disease-relevant mechanism of action, and multiple molecules are currently undergoing oncology clinical trials. This work describes an efficiency analysis of published GSK pan-BET bromodomain inhibitors, which drove a strategic choice to focus on the identification of a ligand-efficient KAc mimetic with the hypothesis that lipophilic efficiency could be drastically improved during optimization. This focus drove the discovery of the highly ligand-efficient and structurally distinct benzoazepinone KAc mimetic. Following crystallography to identify suitable growth vectors, the benzoazepinone core was optimized through an explore-exploit structure-activity relationship (SAR) approach while carefully monitoring lipophilic efficiency to deliver I-BET432 () as an oral candidate quality molecule.
PubMed: 36378954
DOI: 10.1021/acs.jmedchem.2c01102
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.604 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon